India Globalization Capital Key Executives
This section highlights India Globalization Capital's key executives, including their titles and compensation details.
Find Contacts at India Globalization Capital
(Showing 0 of )
India Globalization Capital Earnings
This section highlights India Globalization Capital's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand. The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts. It operates in the United States, India, Colombia, and Hong Kong. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
$0.29
Stock Price
$23.43M
Market Cap
67
Employees
Potomac, MD
Location
Financial Statements
Access annual & quarterly financial statements for India Globalization Capital, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.34M | $911.00K | $397.00K | $898.00K | $4.07M |
| Cost of Revenue | $612.00K | $469.00K | $203.00K | $785.00K | $3.96M |
| Gross Profit | $733.00K | $442.00K | $194.00K | $113.00K | $115.00K |
| Gross Profit Ratio | 54.50% | 48.50% | 48.87% | 12.60% | 2.82% |
| Research and Development Expenses | $3.77M | $3.46M | $2.33M | $929.00K | $1.01M |
| General and Administrative Expenses | $- | $- | $- | $- | $5.97M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $6.76M | $8.55M | $13.29M | $7.91M | $5.97M |
| Other Expenses | $- | $65.00K | $461.00K | $82.00K | $331.00K |
| Operating Expenses | $10.53M | $12.01M | $15.62M | $8.84M | $6.98M |
| Cost and Expenses | $11.14M | $12.48M | $15.82M | $9.62M | $10.94M |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $637.00K | $657.00K | $651.00K | $478.00K | $144.00K |
| EBITDA | $-9.16M | $-10.91M | $-14.78M | $-8.25M | $-6.72M |
| EBITDA Ratio | -681.12% | -1198.02% | -3709.82% | -899.44% | -145.83% |
| Operating Income | $-9.80M | $-11.57M | $-15.43M | $-8.72M | $-6.86M |
| Operating Income Ratio | -728.48% | -1270.14% | -3886.15% | -971.49% | -168.57% |
| Total Other Income Expenses Net | $-3.20M | $65.00K | $412.00K | $-87.00K | $-451.00K |
| Income Before Tax | $-13.00M | $-11.51M | $-15.02M | $-8.81M | $-7.32M |
| Income Before Tax Ratio | -966.54% | -1263.01% | -3782.37% | -981.18% | -179.64% |
| Income Tax Expense | $- | $-65.00K | $-412.00K | $169.00K | $782.00K |
| Net Income | $-13.00M | $-11.44M | $-14.60M | $-8.98M | $-8.10M |
| Net Income Ratio | -966.54% | -1255.87% | -3678.59% | -1000.00% | -198.85% |
| EPS | $-0.22 | $-0.22 | $-0.29 | $-0.21 | $-0.21 |
| EPS Diluted | $-0.22 | $-0.22 | $-0.29 | $-0.21 | $-0.21 |
| Weighted Average Shares Outstanding | 58.84M | 52.58M | 49.99M | 41.96M | 39.49M |
| Weighted Average Shares Outstanding Diluted | 58.84M | 52.58M | 49.99M | 41.96M | 39.49M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $257.00K | $412.00K | $272.00K | $295.00K | $204.00K | $291.00K | $555.00K | $166.00K | $332.00K | $202.00K | $212.00K | $122.00K | $142.00K | $56.00K | $77.00K | $81.00K | $108.00K | $125.00K | $584.00K | $29.00K |
| Cost of Revenue | $153.00K | $214.00K | $109.00K | $124.00K | $211.00K | $117.00K | $300.00K | $103.00K | $230.00K | $67.00K | $70.00K | $54.00K | $80.00K | $18.00K | $51.00K | $54.00K | $94.00K | $99.00K | $538.00K | $13.00K |
| Gross Profit | $104.00K | $198.00K | $163.00K | $171.00K | $-7.00K | $174.00K | $255.00K | $63.00K | $102.00K | $135.00K | $142.00K | $68.00K | $62.00K | $38.00K | $26.00K | $27.00K | $14.00K | $26.00K | $46.00K | $16.00K |
| Gross Profit Ratio | 40.47% | 48.10% | 59.90% | 58.00% | -3.40% | 59.80% | 45.90% | 38.00% | 30.70% | 66.80% | 67.00% | 55.70% | 43.70% | 67.90% | 33.80% | 33.30% | 13.00% | 20.80% | 7.90% | 55.17% |
| Research and Development Expenses | $852.00K | $917.00K | $889.00K | $855.00K | $903.00K | $1.27M | $747.00K | $493.00K | $806.00K | $768.00K | $1.39M | $1.23M | $377.00K | $276.00K | $444.00K | $334.00K | $154.00K | $219.00K | $222.00K | $247.00K |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $1.85M | $- | $1.85M | $- | $4.11M | $- | $4.11M | $- | $1.48M | $- | $1.48M | $- | $2.21M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $1.75M | $- | $- | $- | $1.23M | $- | $- | $- | $1.00M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.13M | $1.04M | $1.67M | $1.49M | $2.09M | $1.40M | $1.65M | $3.61M | $1.57M | $1.85M | $1.55M | $5.34M | $2.07M | $4.11M | $1.78M | $2.48M | $2.19M | $1.48M | $1.75M | $2.21M |
| Other Expenses | $- | $- | $- | $7.00K | $32.00K | $40.00K | $64.00K | $9.00K | $29.00K | $46.00K | $17.00K | $10.00K | $4.00K | $4.00K | $443.00K | $11.00K | $3.00K | $19.00K | $49.00K | $71.00K |
| Operating Expenses | $1.98M | $1.96M | $2.56M | $2.34M | $2.99M | $2.67M | $2.39M | $4.10M | $2.38M | $2.62M | $2.94M | $6.57M | $2.45M | $4.39M | $2.22M | $2.82M | $2.34M | $1.70M | $1.98M | $2.46M |
| Cost and Expenses | $2.13M | $2.17M | $2.67M | $2.46M | $3.20M | $2.78M | $2.69M | $4.21M | $2.61M | $2.69M | $3.01M | $6.62M | $2.53M | $4.40M | $2.27M | $2.87M | $2.43M | $1.80M | $2.52M | $2.47M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $145.00K | $162.00K | $164.00K | $159.00K | $158.00K | $155.00K | $153.00K | $172.00K | $170.00K | $162.00K | $206.00K | $124.00K | $163.00K | $157.00K | $170.00K | $127.00K | $108.00K | $77.00K | $75.00K |
| EBITDA | $-1.88M | $-1.61M | $-2.22M | $-2.01M | $-2.84M | $-2.33M | $-1.96M | $-3.88M | $-2.11M | $-2.32M | $-2.64M | $-6.30M | $-2.22M | $-4.18M | $-2.04M | $-2.62M | $-2.20M | $-1.57M | $-1.85M | $-2.37M |
| EBITDA Ratio | -730.74% | -391.99% | -814.71% | -435.25% | -1391.67% | -856.01% | -357.48% | -2340.96% | -634.34% | -1147.52% | -1245.28% | -5183.61% | -1562.68% | -7473.21% | -2597.40% | -3240.74% | -2036.11% | -1254.40% | -317.47% | -5468.97% |
| Operating Income | $-1.88M | $-1.76M | $-2.40M | $-2.17M | $-3.00M | $-2.49M | $-2.14M | $-4.04M | $-2.28M | $-2.49M | $-2.80M | $-6.50M | $-2.38M | $-4.35M | $-2.19M | $-2.79M | $-2.33M | $-1.68M | $-1.93M | $-2.44M |
| Operating Income Ratio | -730.74% | -427.18% | -880.88% | -735.59% | -1469.61% | -856.01% | -385.41% | -2433.13% | -686.14% | -1231.68% | -1321.70% | -5328.69% | -1679.58% | -7764.29% | -2849.35% | -3445.68% | -2153.70% | -1340.80% | -330.65% | -8424.14% |
| Total Other Income Expenses Net | $49.00K | $43.00K | $18.00K | $-715.00K | $-2.59M | $40.00K | $64.00K | $9.00K | $29.00K | $46.00K | $17.00K | $-2.00K | $4.00K | $4.00K | $406.00K | $-158.00K | $3.00K | $19.00K | $49.00K | $-711.00K |
| Income Before Tax | $-1.83M | $-1.72M | $-2.38M | $-2.88M | $-5.59M | $-2.45M | $-2.08M | $-4.03M | $-2.25M | $-2.44M | $-2.79M | $-6.50M | $-2.38M | $-4.34M | $-1.79M | $-2.95M | $-2.32M | $-1.66M | $-1.88M | $-3.15M |
| Income Before Tax Ratio | -711.67% | -416.75% | -874.26% | -977.97% | -2739.71% | -842.27% | -373.87% | -2427.71% | -677.41% | -1208.91% | -1313.68% | -5330.33% | -1676.76% | -7757.14% | -2322.08% | -3640.74% | -2150.93% | -1325.60% | -322.26% | -10875.86% |
| Income Tax Expense | $- | $- | $- | $722.00K | $- | $-158.00K | $111.72K | $-9.00K | $-29.00K | $-46.00K | $- | $2.00K | $42.00K | $- | $37.00K | $-4.00K | $- | $- | $- | $782.00K |
| Net Income | $-1.83M | $-1.72M | $-2.38M | $-2.88M | $-5.59M | $-2.45M | $-2.08M | $-4.02M | $-2.22M | $-2.40M | $-2.79M | $-6.50M | $-2.38M | $-4.34M | $-1.79M | $-2.95M | $-2.32M | $-1.66M | $-1.88M | $-3.15M |
| Net Income Ratio | -711.67% | -416.75% | -874.26% | -977.97% | -2739.71% | -842.27% | -373.87% | -2422.29% | -668.67% | -1186.14% | -1313.68% | -5331.97% | -1676.76% | -7757.14% | -2322.08% | -3640.74% | -2150.93% | -1325.60% | -322.26% | -10875.86% |
| EPS | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.09 | $-0.05 | $-0.04 | $-0.08 | $-0.04 | $-0.05 | $-0.05 | $-0.16 | $-0.05 | $-0.09 | $-0.04 | $-0.07 | $-0.06 | $-0.04 | $-0.05 | $-0.08 |
| EPS Diluted | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.09 | $-0.05 | $-0.04 | $-0.08 | $-0.04 | $-0.05 | $-0.05 | $-0.16 | $-0.05 | $-0.09 | $-0.04 | $-0.07 | $-0.06 | $-0.04 | $-0.05 | $-0.08 |
| Weighted Average Shares Outstanding | 77.63M | 76.01M | 72.81M | 66.16M | 63.73M | 54.30M | 53.08M | 53.08M | 53.06M | 52.19M | 51.62M | 41.96M | 51.05M | 49.95M | 47.91M | 41.30M | 41.30M | 41.24M | 40.19M | 39.33M |
| Weighted Average Shares Outstanding Diluted | 77.63M | 76.01M | 72.81M | 66.16M | 63.73M | 54.30M | 53.08M | 53.08M | 53.06M | 52.19M | 51.62M | 41.96M | 51.05M | 49.95M | 47.91M | 41.30M | 41.30M | 41.24M | 40.19M | 40.19M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.20M | $3.20M | $10.46M | $14.55M | $7.26M |
| Short Term Investments | $- | $154.00K | $- | $80.00K | $5.08M |
| Cash and Short Term Investments | $1.20M | $3.35M | $10.46M | $14.63M | $12.34M |
| Net Receivables | $39.00K | $107.00K | $125.00K | $175.00K | $133.00K |
| Inventory | $1.54M | $2.65M | $3.55M | $5.48M | $4.25M |
| Other Current Assets | $854.00K | $548.00K | $974.00K | $3.32M | $1.04M |
| Total Current Assets | $3.71M | $6.47M | $15.11M | $23.52M | $17.76M |
| Property Plant Equipment Net | $3.89M | $8.54M | $9.87M | $11.33M | $10.35M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $1.62M | $1.17M | $917.00K | $407.00K | $252.00K |
| Goodwill and Intangible Assets | $1.62M | $1.17M | $917.00K | $407.00K | $252.00K |
| Long Term Investments | $- | $951.00K | $368.00K | $12.00K | $11.00K |
| Tax Assets | $- | $-951.00K | $-368.00K | $- | $- |
| Other Non-Current Assets | $688.00K | $1.00M | $937.00K | $603.00K | $610.00K |
| Total Non-Current Assets | $6.20M | $10.71M | $11.72M | $12.35M | $11.23M |
| Other Assets | $- | $- | $-1.00K | $- | $- |
| Total Assets | $9.90M | $17.18M | $26.83M | $35.87M | $28.98M |
| Account Payables | $773.00K | $530.00K | $981.00K | $476.00K | $762.00K |
| Short Term Debt | $124.00K | $133.00K | $126.00K | $304.00K | $50.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $877.00K | $- | $1.16M | $836.00K |
| Other Current Liabilities | $1.44M | $1.24M | $1.33M | $1.59M | $1.13M |
| Total Current Liabilities | $2.34M | $1.90M | $2.44M | $2.37M | $1.95M |
| Long Term Debt | $221.00K | $348.00K | $485.00K | $681.00K | $485.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $20.00K | $21.00K | $16.00K | $15.00K | $16.00K |
| Total Non-Current Liabilities | $241.00K | $369.00K | $501.00K | $696.00K | $501.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $2.58M | $2.27M | $2.94M | $3.06M | $2.45M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $124.41M | $118.97M | $116.02M | $109.72M | $94.75M |
| Retained Earnings | $-113.67M | $-100.67M | $-89.16M | $-74.14M | $-65.37M |
| Accumulated Other Comprehensive Income Loss | $-3.42M | $-3.39M | $-2.97M | $-2.77M | $-2.85M |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $7.32M | $14.91M | $23.89M | $32.80M | $26.54M |
| Total Equity | $7.32M | $14.91M | $23.89M | $32.80M | $26.54M |
| Total Liabilities and Stockholders Equity | $9.90M | $17.18M | $26.83M | $35.87M | $28.98M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.90M | $17.18M | $26.83M | $35.87M | $28.98M |
| Total Investments | $686.00K | $154.00K | $368.00K | $92.00K | $5.09M |
| Total Debt | $345.00K | $481.00K | $488.00K | $985.00K | $535.00K |
| Net Debt | $-853.00K | $-2.71M | $-9.97M | $-13.56M | $-6.72M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $470.00K | $1.55M | $1.82M | $1.20M | $1.38M | $3.03M | $1.72M | $3.20M | $4.95M | $6.62M | $8.05M | $10.46M | $11.94M | $14.40M | $13.32M | $14.55M | $968.00K | $1.15M | $2.70M | $7.26M |
| Short Term Investments | $- | $- | $- | $- | $- | $98.00K | $227.00K | $154.00K | $88.00K | $193.00K | $- | $- | $- | $- | $- | $80.00K | $2.00M | $3.85M | $5.10M | $5.08M |
| Cash and Short Term Investments | $470.00K | $1.55M | $1.82M | $1.20M | $1.38M | $3.12M | $1.95M | $3.35M | $5.03M | $6.82M | $8.05M | $10.46M | $11.94M | $14.40M | $13.32M | $14.63M | $2.97M | $5.00M | $7.80M | $12.34M |
| Net Receivables | $92.00K | $88.00K | $28.00K | $39.00K | $92.00K | $137.00K | $225.00K | $107.00K | $251.00K | $189.00K | $147.00K | $125.00K | $164.00K | $138.00K | $162.00K | $175.00K | $226.00K | $241.00K | $264.00K | $133.00K |
| Inventory | $1.43M | $1.51M | $1.51M | $1.54M | $1.97M | $2.64M | $2.64M | $2.65M | $3.75M | $3.75M | $3.62M | $3.55M | $5.43M | $5.50M | $5.48M | $5.48M | $5.16M | $6.68M | $6.52M | $4.25M |
| Other Current Assets | $1.06M | $1.11M | $1.25M | $1.00M | $237.00K | $276.00K | $380.00K | $548.00K | $361.00K | $441.00K | $905.00K | $974.00K | $747.00K | $1.67M | $3.23M | $3.32M | $3.07M | $1.76M | $1.41M | $1.04M |
| Total Current Assets | $3.05M | $4.25M | $4.41M | $3.71M | $3.58M | $6.12M | $5.08M | $6.47M | $9.35M | $11.20M | $12.73M | $15.11M | $19.24M | $21.70M | $22.19M | $23.52M | $11.42M | $13.69M | $16.00M | $17.76M |
| Property Plant Equipment Net | $3.48M | $3.63M | $3.78M | $3.89M | $5.50M | $8.21M | $8.40M | $8.54M | $8.67M | $8.86M | $9.58M | $9.87M | $11.00M | $11.10M | $11.24M | $11.33M | $11.48M | $11.44M | $11.16M | $10.35M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $1.87M | $1.80M | $1.72M | $1.62M | $1.18M | $1.18M | $1.18M | $1.17M | $1.02M | $952.00K | $937.00K | $917.00K | $426.00K | $411.00K | $405.00K | $407.00K | $384.00K | $344.00K | $275.00K | $252.00K |
| Goodwill and Intangible Assets | $1.87M | $1.80M | $1.72M | $1.62M | $1.18M | $1.18M | $1.18M | $1.17M | $1.02M | $952.00K | $937.00K | $917.00K | $426.00K | $411.00K | $405.00K | $407.00K | $384.00K | $344.00K | $275.00K | $252.00K |
| Long Term Investments | $- | $- | $- | $686.00K | $946.00K | $947.00K | $951.00K | $951.00K | $751.00K | $751.00K | $354.00K | $368.00K | $11.00K | $11.00K | $11.00K | $12.00K | $261.00K | $261.00K | $260.00K | $11.00K |
| Tax Assets | $- | $- | $- | $-686.00K | $- | $-947.00K | $-951.00K | $-951.00K | $-751.00K | $-751.00K | $-354.00K | $-368.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $681.00K | $687.00K | $688.00K | $688.00K | $53.00K | $998.00K | $1.02M | $1.00M | $1.03M | $950.00K | $922.00K | $937.00K | $612.00K | $611.00K | $596.00K | $603.00K | $619.00K | $616.00K | $606.00K | $610.00K |
| Total Non-Current Assets | $6.03M | $6.12M | $6.19M | $6.20M | $7.68M | $10.39M | $10.60M | $10.71M | $10.72M | $10.76M | $11.44M | $11.72M | $12.05M | $12.13M | $12.25M | $12.35M | $12.74M | $12.66M | $12.30M | $11.23M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00K | $- | $1.00K | $- | $- | $- | $- | $- | $- |
| Total Assets | $9.08M | $10.37M | $10.59M | $9.90M | $11.26M | $16.51M | $15.67M | $17.18M | $20.07M | $21.96M | $24.17M | $26.83M | $31.29M | $33.84M | $34.44M | $35.87M | $24.16M | $26.35M | $28.30M | $28.98M |
| Account Payables | $835.00K | $768.00K | $771.00K | $773.00K | $648.00K | $549.00K | $672.00K | $530.00K | $466.00K | $456.00K | $456.00K | $981.00K | $357.00K | $418.00K | $567.00K | $476.00K | $875.00K | $975.00K | $1.10M | $762.00K |
| Short Term Debt | $- | $134.00K | $133.00K | $124.00K | $127.00K | $130.00K | $129.00K | $133.00K | $130.00K | $128.00K | $3.00K | $126.00K | $3.00K | $3.00K | $3.00K | $304.00K | $340.00K | $196.00K | $- | $50.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $1.02M | $- | $1.13M | $882.00K | $877.00K | $- | $- | $819.00K | $- | $662.00K | $1.26M | $1.07M | $1.16M | $425.00K | $517.00K | $- | $836.00K |
| Other Current Liabilities | $1.82M | $1.90M | $1.58M | $1.44M | $1.16M | $1.43M | $1.33M | $1.24M | $760.00K | $798.00K | $1.20M | $1.33M | $919.00K | $1.59M | $1.54M | $1.59M | $703.00K | $727.00K | $1.22M | $1.13M |
| Total Current Liabilities | $2.66M | $2.80M | $2.49M | $2.34M | $1.94M | $2.11M | $2.13M | $1.90M | $1.36M | $1.38M | $1.66M | $2.44M | $1.28M | $2.02M | $2.11M | $2.37M | $1.92M | $1.90M | $2.32M | $1.95M |
| Long Term Debt | $146.00K | $170.00K | $205.00K | $221.00K | $253.00K | $285.00K | $319.00K | $348.00K | $382.00K | $417.00K | $451.00K | $485.00K | $519.00K | $550.00K | $580.00K | $681.00K | $756.00K | $834.00K | $1.10M | $485.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $16.00K | $20.00K | $20.00K | $20.00K | $17.00K | $17.00K | $21.00K | $21.00K | $15.00K | $15.00K | $16.00K | $16.00K | $15.00K | $15.00K | $15.00K | $15.00K | $17.00K | $16.00K | $16.00K | $16.00K |
| Total Non-Current Liabilities | $162.00K | $190.00K | $225.00K | $241.00K | $270.00K | $302.00K | $340.00K | $369.00K | $397.00K | $432.00K | $467.00K | $501.00K | $534.00K | $565.00K | $595.00K | $696.00K | $773.00K | $850.00K | $1.12M | $501.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $2.82M | $2.99M | $2.71M | $2.58M | $2.21M | $2.41M | $2.47M | $2.27M | $1.75M | $1.81M | $2.13M | $2.94M | $1.81M | $2.58M | $2.71M | $3.06M | $2.69M | $2.75M | $3.44M | $2.45M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.37M | $1 | $- | $- | $- | $- | $2.77M | $- | $1 | $- | $- |
| Common Stock | $129.31M | $128.58M | $127.35M | $124.41M | $123.26M | $122.73M | $119.32M | $118.97M | $118.38M | $117.90M | $117.17M | $116.02M | $114.89M | $114.37M | $110.53M | $109.72M | $95.43M | $95.27M | $95.02M | $94.75M |
| Retained Earnings | $-119.59M | $-117.76M | $-116.04M | $-113.67M | $-110.78M | $-105.19M | $-102.74M | $-100.67M | $-96.64M | $-94.39M | $-91.94M | $-89.16M | $-82.66M | $-80.28M | $-75.93M | $-74.14M | $-71.23M | $-68.91M | $-67.25M | $-65.37M |
| Accumulated Other Comprehensive Income Loss | $-3.46M | $-3.44M | $-3.43M | $-3.42M | $-3.42M | $-3.44M | $-3.38M | $-3.39M | $-3.43M | $-3.37M | $-3.19M | $-2.97M | $-2.76M | $-2.84M | $-2.86M | $-2.77M | $-2.73M | $-2.77M | $-2.91M | $-2.85M |
| Other Total Stockholders Equity | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $6.26M | $7.38M | $7.88M | $7.32M | $9.05M | $14.10M | $13.20M | $14.91M | $18.32M | $20.14M | $22.04M | $23.89M | $29.48M | $31.26M | $31.74M | $32.80M | $21.47M | $23.60M | $24.86M | $26.54M |
| Total Equity | $6.26M | $7.38M | $7.88M | $7.32M | $9.05M | $14.10M | $13.20M | $14.91M | $18.32M | $20.14M | $22.04M | $23.89M | $29.48M | $31.26M | $31.74M | $32.80M | $21.47M | $23.60M | $24.86M | $26.54M |
| Total Liabilities and Stockholders Equity | $9.08M | $10.37M | $10.59M | $9.90M | $11.26M | $16.51M | $15.67M | $17.18M | $20.07M | $21.96M | $24.17M | $26.83M | $31.29M | $33.84M | $34.44M | $35.87M | $24.16M | $26.35M | $28.30M | $28.98M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $9.08M | $10.37M | $10.59M | $9.90M | $11.26M | $16.51M | $15.67M | $17.18M | $20.07M | $21.96M | $24.17M | $26.83M | $31.29M | $33.84M | $34.44M | $35.87M | $24.16M | $26.35M | $28.30M | $28.98M |
| Total Investments | $- | $- | $686.00K | $686.00K | $946.00K | $98.00K | $227.00K | $154.00K | $88.00K | $193.00K | $354.00K | $368.00K | $11.00K | $11.00K | $11.00K | $92.00K | $2.26M | $4.11M | $5.36M | $5.09M |
| Total Debt | $146.00K | $304.00K | $338.00K | $345.00K | $380.00K | $415.00K | $448.00K | $481.00K | $512.00K | $545.00K | $454.00K | $488.00K | $522.00K | $553.00K | $583.00K | $985.00K | $1.01M | $1.03M | $1.10M | $535.00K |
| Net Debt | $-324.00K | $-1.24M | $-1.49M | $-853.00K | $-998.00K | $-2.61M | $-1.27M | $-2.71M | $-4.43M | $-6.08M | $-7.60M | $-9.97M | $-11.42M | $-13.85M | $-12.74M | $-13.56M | $40.00K | $-121.00K | $-1.60M | $-6.72M |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-13.00M | $-11.51M | $-15.02M | $-8.81M | $-7.32M |
| Depreciation and Amortization | $637.00K | $657.00K | $651.00K | $478.00K | $144.00K |
| Deferred Income Tax | $- | $-451.00K | $- | $- | $- |
| Stock Based Compensation | $1.77M | $2.84M | $2.20M | $658.00K | $770.00K |
| Change in Working Capital | $1.89M | $794.00K | $2.54M | $-3.29M | $-3.06M |
| Accounts Receivables | $-25.00K | $5.00K | $50.00K | $-42.00K | $-49.00K |
| Inventory | $1.01M | $897.00K | $1.93M | $-1.23M | $-4.00M |
| Accounts Payables | $243.00K | $-451.00K | $504.00K | $-287.00K | $442.00K |
| Other Working Capital | $668.00K | $-451.00K | $52.00K | $-1.73M | $547.00K |
| Other Non Cash Items | $3.50M | $616.00K | $2.17M | $169.00K | $782.00K |
| Net Cash Provided by Operating Activities | $-5.20M | $-7.05M | $-7.46M | $-10.80M | $-8.68M |
| Investments in Property Plant and Equipment | $-138.00K | $-619.00K | $-742.00K | $-1.59M | $-4.47M |
| Acquisitions Net | $- | $538.00K | $- | $122.00K | $- |
| Purchases of Investments | $- | $-154.00K | $- | $-149.00K | $-5.08M |
| Sales Maturities of Investments | $- | $-538.00K | $- | $5.08M | $- |
| Other Investing Activities | $-179.00K | $538.00K | $-506.00K | $-75.00K | $-5.08M |
| Net Cash Used for Investing Activities | $-317.00K | $-235.00K | $-742.00K | $3.39M | $-9.55M |
| Debt Repayment | $-3.00K | $-3.00K | $-3.00K | $530.00K | $- |
| Common Stock Issued | $3.53M | $103.00K | $4.14M | $14.16M | $-59.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $-59.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $4.14M | $- | $- |
| Net Cash Used Provided by Financing Activities | $3.52M | $100.00K | $4.14M | $14.69M | $-59.00K |
| Effect of Forex Changes on Cash | $-6.00K | $-82.00K | $-26.00K | $15.00K | $-69.00K |
| Net Change in Cash | $-2.00M | $-7.26M | $-4.09M | $7.29M | $-18.35M |
| Cash at End of Period | $1.20M | $3.20M | $10.46M | $14.55M | $7.26M |
| Cash at Beginning of Period | $3.20M | $10.46M | $14.55M | $7.26M | $25.61M |
| Operating Cash Flow | $-5.20M | $-7.05M | $-7.46M | $-10.80M | $-8.68M |
| Capital Expenditure | $-515.00K | $-619.00K | $-742.00K | $-1.59M | $-4.47M |
| Free Cash Flow | $-5.71M | $-7.67M | $-8.20M | $-12.39M | $-13.14M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.83M | $-1.72M | $-2.38M | $-2.88M | $-5.59M | $-2.45M | $-2.08M | $-4.03M | $-2.25M | $-2.44M | $-2.79M | $-6.50M | $-2.38M | $-4.34M | $-1.79M | $-2.95M | $-2.32M | $-1.66M | $-1.88M | $-3.15M |
| Depreciation and Amortization | $157.00K | $145.00K | $162.00K | $164.00K | $159.00K | $158.00K | $155.00K | $153.00K | $172.00K | $170.00K | $162.00K | $165.00K | $166.00K | $163.00K | $157.00K | $166.00K | $127.00K | $108.00K | $77.00K | $75.00K |
| Deferred Income Tax | $- | $- | $- | $759.00K | $-725.00K | $- | $-34.00K | $- | $- | $- | $- | $-37.00K | $- | $- | $37.00K | $- | $- | $- | $- | $- |
| Stock Based Compensation | $381.00K | $402.00K | $402.00K | $340.00K | $526.00K | $550.00K | $357.00K | $583.00K | $484.00K | $624.00K | $1.15M | $1.12M | $523.00K | $424.00K | $125.00K | $135.00K | $158.00K | $199.00K | $166.00K | $246.00K |
| Change in Working Capital | $- | $-62.00K | $62.00K | $1.67M | $-52.00K | $124.00K | $148.00K | $1.65M | $-49.00K | $-15.00K | $-793.00K | $3.48M | $-730.00K | $-263.00K | $48.00K | $-26.00K | $193.00K | $-1.11M | $-2.35M | $58.00K |
| Accounts Receivables | $-5.00K | $-16.00K | $11.00K | $-39.00K | $44.00K | $88.00K | $-118.00K | $132.00K | $-62.00K | $-42.00K | $-23.00K | $39.00K | $-25.00K | $23.00K | $13.00K | $51.00K | $41.00K | $23.00K | $-157.00K | $24.00K |
| Inventory | $77.00K | $- | $30.00K | $1.02M | $-23.00K | $5.00K | $10.00K | $1.10M | $2.00K | $-128.00K | $-74.00K | $1.88M | $71.00K | $-22.00K | $2.00K | $-322.00K | $1.53M | $-162.00K | $-2.28M | $-661.00K |
| Accounts Payables | $66.00K | $-2.00K | $-2.00K | $126.00K | $98.00K | $-123.00K | $142.00K | $65.00K | $8.00K | $- | $-524.00K | $621.00K | $-61.00K | $-146.00K | $90.00K | $-399.00K | $-127.00K | $-138.00K | $377.00K | $442.00K |
| Other Working Capital | $21.00K | $-44.00K | $23.00K | $571.00K | $-171.00K | $154.00K | $-34.00K | $357.00K | $3.00K | $155.00K | $-172.00K | $942.00K | $-715.00K | $-118.00K | $-57.00K | $644.00K | $-1.25M | $-835.00K | $-292.00K | $695.00K |
| Other Non Cash Items | $-26.00K | $236.00K | $- | $-253.00K | $4.09M | $1.00K | $-19.00K | $126.00K | $-6.00K | $-23.00K | $68.00K | $845.00K | $828.00K | $1.72M | $-430.00K | $169.00K | $-127.00K | $-138.00K | $377.00K | $782.00K |
| Net Cash Provided by Operating Activities | $-1.32M | $-996.00K | $-1.75M | $-526.00K | $-1.59M | $-1.62M | $-1.47M | $-1.52M | $-1.65M | $-1.69M | $-2.20M | $-887.00K | $-2.42M | $-2.30M | $-1.85M | $-2.50M | $-1.84M | $-2.46M | $-3.99M | $-1.99M |
| Investments in Property Plant and Equipment | $-27.00K | $-29.00K | $-38.00K | $-325.00K | $-87.00K | $-55.00K | $-48.00K | $-475.00K | $-84.00K | $98.00K | $-158.00K | $-553.00K | $-49.00K | $-45.00K | $-95.00K | $-119.00K | $-196.00K | $-307.00K | $-970.00K | $-723.00K |
| Acquisitions Net | $- | $- | $- | $2.00K | $- | $-1.00K | $43.00K | $299.00K | $-38.00K | $277.00K | $- | $- | $- | $- | $- | $47.00K | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $281.00K | $- | $-127.00K | $- | $-66.00K | $105.00K | $-193.00K | $- | $- | $- | $- | $- | $149.00K | $- | $17.00K | $-166.00K | $-18.00K |
| Sales Maturities of Investments | $- | $- | $- | $-154.00K | $26.00K | $128.00K | $- | $-299.00K | $38.00K | $-182.00K | $- | $- | $- | $- | $- | $2.00M | $1.85M | $- | $- | $- |
| Other Investing Activities | $-77.00K | $-36.00K | $-93.00K | $-460.00K | $7.00K | $127.00K | $15.00K | $299.00K | $-38.00K | $182.00K | $-31.00K | $-469.00K | $-22.00K | $-13.00K | $-2.00K | $47.00K | $1.81M | $1.23M | $-192.00K | $-27.00K |
| Net Cash Used for Investing Activities | $-104.00K | $-65.00K | $-131.00K | $-323.00K | $-61.00K | $72.00K | $-5.00K | $-242.00K | $-17.00K | $182.00K | $-158.00K | $-553.00K | $-49.00K | $-45.00K | $-95.00K | $1.93M | $1.65M | $941.00K | $-1.14M | $-741.00K |
| Debt Repayment | $-1.00K | $-1.00K | $-1.00K | $- | $-1.00K | $-1.00K | $-1.00K | $-1.00K | $- | $-1.00K | $-1.00K | $-1.00K | $-1.00K | $-1.00K | $- | $- | $- | $-50.00K | $580.00K | $- |
| Common Stock Issued | $346.00K | $795.00K | $2.51M | $667.00K | $- | $2.86M | $357.00K | $-1.15M | $- | $103.00K | $1.15M | $- | $- | $3.42M | $726.00K | $14.16M | $- | $- | $166.00K | $-18.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-18.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $667.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-59.00K |
| Net Cash Used Provided by Financing Activities | $345.00K | $794.00K | $2.51M | $667.00K | $-1.00K | $2.86M | $-1.00K | $-1.00K | $- | $102.00K | $-1.00K | $-1.00K | $-1.00K | $3.42M | $726.00K | $14.16M | $- | $-50.00K | $580.00K | $-77.00K |
| Effect of Forex Changes on Cash | $- | $-11.00K | $2.00K | $2.00K | $1.00K | $-10.00K | $1.00K | $11.00K | $-13.00K | $-28.00K | $-52.00K | $-40.00K | $14.00K | $9.00K | $-9.00K | $-1.00K | $8.00K | $19.00K | $-11.00K | $-60.00K |
| Net Change in Cash | $-1.08M | $-278.00K | $626.00K | $-180.00K | $-1.65M | $1.30M | $-1.47M | $-1.75M | $-1.68M | $-1.43M | $-2.41M | $-1.48M | $-2.46M | $1.08M | $-1.23M | $13.58M | $-183.00K | $-1.55M | $-4.55M | $-2.87M |
| Cash at End of Period | $470.00K | $1.55M | $1.82M | $1.20M | $1.38M | $3.03M | $1.72M | $3.20M | $4.95M | $6.62M | $8.05M | $10.46M | $11.94M | $14.40M | $13.32M | $14.55M | $968.00K | $1.15M | $2.70M | $7.26M |
| Cash at Beginning of Period | $1.55M | $1.82M | $1.20M | $1.38M | $3.03M | $1.72M | $3.20M | $4.95M | $6.62M | $8.05M | $10.46M | $11.94M | $14.40M | $13.32M | $14.55M | $968.00K | $1.15M | $2.70M | $7.26M | $10.13M |
| Operating Cash Flow | $-1.32M | $-996.00K | $-1.75M | $-526.00K | $-1.59M | $-1.62M | $-1.47M | $-1.52M | $-1.65M | $-1.69M | $-2.20M | $-887.00K | $-2.42M | $-2.30M | $-1.85M | $-2.50M | $-1.84M | $-2.46M | $-3.99M | $-1.99M |
| Capital Expenditure | $-27.00K | $64.00K | $-131.00K | $-325.00K | $-87.00K | $-55.00K | $-48.00K | $-475.00K | $-84.00K | $98.00K | $-158.00K | $-553.00K | $-49.00K | $-45.00K | $-95.00K | $-119.00K | $-196.00K | $-307.00K | $-970.00K | $-723.00K |
| Free Cash Flow | $-1.34M | $-932.00K | $-1.88M | $-851.00K | $-1.67M | $-1.67M | $-1.52M | $-1.99M | $-1.73M | $-1.59M | $-2.35M | $-1.44M | $-2.47M | $-2.35M | $-1.95M | $-2.62M | $-2.04M | $-2.77M | $-4.96M | $-2.72M |
India Globalization Capital Dividends
Explore India Globalization Capital's dividend history, including dividend yield, payout ratio, and historical payments.
India Globalization Capital News
Read the latest news about India Globalization Capital, including recent articles, headlines, and updates.
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer's disease. Based on the interim analysis at week 2 sleep disturbance was reduced by about 71% (p=.012) and at week 6 about 78% (p=.02) for those on the active medication.
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the Company's clinical footprint.
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital in St. Petersburg, Florida as part of its ongoing Phase 2 CALMA trial evaluating IGC-AD1, the Company's lead therapeutic candidate, for the treatment of agitation in Alzheimer's dementia. IGC-AD1 is a combination therapy designed to address agitation in Alzheimer's disease.
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.
POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"
POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts.
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health solutions. Holiby is scaling its commercial strategy through direct-to-consumer e-commerce, white-label and private-label partnerships, and targeted influencer marketing and digital advertising.
IGC Pharma Reports Third Quarter Fiscal 2025 Results
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr.
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
- Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion into the rapidly growing $75 billion wellness industry establishes a new revenue stream while IGC Pharma continues advancing its pharmaceutical pipeline focused on treatments for Alzheimer's disease and metabolic disorders.
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer's disease (AD) and improve patient outcomes.
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery.
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's). The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025.
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders.
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies
POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series. In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies.
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
- Company Expands Phase 2 trial to Canada - POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of Alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication.
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH").
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for IGC.